D B Ollila

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. pmc Distance to diagnosing provider as a measure of access for patients with melanoma
    Karyn B Stitzenberg
    Department of Surgery, School of Medicine, University of North Carolina at Chapel Hill, 3010 Old Clinic Bldg, CB 7213, Chapel Hill, NC 27599 7213, USA
    Arch Dermatol 143:991-8. 2007
  2. ncbi request reprint Breast cancer sentinel node metastases: histopathologic detection and clinical significance
    D B Ollila
    Department of Surgery, University of North Carolina at Chapel Hill, NC 27599 7210, USA
    Cancer Control 8:407-14. 2001
  3. doi request reprint Metastatic melanoma cells in the sentinel node cannot be ignored
    David W Ollila
    Department of Surgery, Division of Surgical Oncology and Endocrine Surgery, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7213, USA
    J Am Coll Surg 208:924-9; discussion 929-30. 2009
  4. ncbi request reprint Feasibility of breast preserving therapy with single fraction in situ radiotherapy delivered intraoperatively
    David W Ollila
    Department of Surgery, UNC Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, 3010 Old Clinic Building, CB 7213, Chapel Hill, NC 27599 7213, USA
    Ann Surg Oncol 14:660-9. 2007
  5. ncbi request reprint Complete metastasectomy in patients with stage IV metastatic melanoma
    David W Ollila
    Division of Surgical Oncology and Endocrine Surgery, University of North Carolina at Chapel Hill School of Medicine, 3010 Old Clinic Building, Chapel Hill, NC 27599, USA
    Lancet Oncol 7:919-24. 2006
  6. ncbi request reprint Surgical management of distant metastases
    David W Ollila
    Division of Surgical Oncology and Endocrine Surgery, University of North Carolina at Chapel Hill, School of Medicine, 3010 Old Clinic Building, Chapel Hill, NC 27599 7213, USA
    Surg Oncol Clin N Am 15:385-98. 2006
  7. ncbi request reprint Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers
    David W Ollila
    Division of Surgical Oncology, Department of Surgery, University of North Carolina, Chapel Hill, NC 27599, USA
    Am J Surg 190:371-5. 2005
  8. doi request reprint Rationale for complete metastasectomy in patients with stage IV metastatic melanoma
    David W Ollila
    Division of Surgical Oncology and Endocrine Surgery, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA
    J Surg Oncol 104:420-4. 2011
  9. ncbi request reprint Axillary lymph node count is lower after neoadjuvant chemotherapy
    Heather Neuman
    Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Am J Surg 191:827-9. 2006
  10. ncbi request reprint Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm)
    Karyn B Stitzenberg
    Division of Surgical Oncology, Department of Surgery, 3010 Old Clinic Building, CB 7213, University of North Carolina, Chapel Hill, NC 27599 7213, USA
    Ann Surg Oncol 11:900-6. 2004

Detail Information

Publications33

  1. pmc Distance to diagnosing provider as a measure of access for patients with melanoma
    Karyn B Stitzenberg
    Department of Surgery, School of Medicine, University of North Carolina at Chapel Hill, 3010 Old Clinic Bldg, CB 7213, Chapel Hill, NC 27599 7213, USA
    Arch Dermatol 143:991-8. 2007
    ..To examine the effect of travel distance and other sociodemographic factors on access to a diagnosing provider for patients with melanoma...
  2. ncbi request reprint Breast cancer sentinel node metastases: histopathologic detection and clinical significance
    D B Ollila
    Department of Surgery, University of North Carolina at Chapel Hill, NC 27599 7210, USA
    Cancer Control 8:407-14. 2001
    ..This review addresses the handling and pathologic examination of the sentinel node (SN), the clinical significance of tumor within the SN, and the risk factors for non-SN tumor involvement...
  3. doi request reprint Metastatic melanoma cells in the sentinel node cannot be ignored
    David W Ollila
    Department of Surgery, Division of Surgical Oncology and Endocrine Surgery, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7213, USA
    J Am Coll Surg 208:924-9; discussion 929-30. 2009
    ..We hypothesize that all patients with metastatic melanoma cells in the sentinel node have potentially life-threatening disease...
  4. ncbi request reprint Feasibility of breast preserving therapy with single fraction in situ radiotherapy delivered intraoperatively
    David W Ollila
    Department of Surgery, UNC Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, 3010 Old Clinic Building, CB 7213, Chapel Hill, NC 27599 7213, USA
    Ann Surg Oncol 14:660-9. 2007
    ..We adapted the technique of Veronesi to deliver IORT prior to tumor excision to improve delivery to the region at risk and reduce the volume of normal tissue irradiated...
  5. ncbi request reprint Complete metastasectomy in patients with stage IV metastatic melanoma
    David W Ollila
    Division of Surgical Oncology and Endocrine Surgery, University of North Carolina at Chapel Hill School of Medicine, 3010 Old Clinic Building, Chapel Hill, NC 27599, USA
    Lancet Oncol 7:919-24. 2006
    ..This Review will present data lending support to the idea that if complete surgical metastasectomy is technically feasible, then surgery should be the first option for properly selected patients with stage IV melanoma...
  6. ncbi request reprint Surgical management of distant metastases
    David W Ollila
    Division of Surgical Oncology and Endocrine Surgery, University of North Carolina at Chapel Hill, School of Medicine, 3010 Old Clinic Building, Chapel Hill, NC 27599 7213, USA
    Surg Oncol Clin N Am 15:385-98. 2006
    ..Until novel drug therapies show efficacy and significantly prolong survival in patients who have stage IV disease, careful consideration should be given to a complete metastectomy if technically feasible...
  7. ncbi request reprint Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers
    David W Ollila
    Division of Surgical Oncology, Department of Surgery, University of North Carolina, Chapel Hill, NC 27599, USA
    Am J Surg 190:371-5. 2005
    ..LM/SL in patients with large breast cancers is controversial. We examined the accuracy of LM/SL prior to neoadjuvant chemotherapy in patients with large (>3.5 cm) breast cancers...
  8. doi request reprint Rationale for complete metastasectomy in patients with stage IV metastatic melanoma
    David W Ollila
    Division of Surgical Oncology and Endocrine Surgery, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA
    J Surg Oncol 104:420-4. 2011
    ..This review article will present data supporting the position that if a complete metastasectomy is technically feasible, then surgery should be strongly considered the first option for properly selected patients with stage IV melanoma...
  9. ncbi request reprint Axillary lymph node count is lower after neoadjuvant chemotherapy
    Heather Neuman
    Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Am J Surg 191:827-9. 2006
    ..We postulated that despite aggressive ALND, a lower lymph node count is more frequent after neoadjuvant chemotherapy...
  10. ncbi request reprint Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm)
    Karyn B Stitzenberg
    Division of Surgical Oncology, Department of Surgery, 3010 Old Clinic Building, CB 7213, University of North Carolina, Chapel Hill, NC 27599 7213, USA
    Ann Surg Oncol 11:900-6. 2004
    ....
  11. pmc Extracapsular extension of the sentinel lymph node metastasis: a predictor of nonsentinel node tumor burden
    Karyn B Stitzenberg
    Department of Surgery, University of North Carolina, 3010 Old Clinic Building, Chapel Hill, NC 27599, USA
    Ann Surg 237:607-12; discussion 612-3. 2003
    ..To identify predictors of nonsentinel node (NSN) tumor involvement in patients with a tumor-involved sentinel node (SN)...
  12. ncbi request reprint In vivo intraoperative radiotherapy: a novel approach to radiotherapy for early stage breast cancer
    Karyn B Stitzenberg
    Department of Surgery, University of North Carolina, Chapel Hill, NC, USA
    Ann Surg Oncol 14:1515-6. 2007
    ..We are investigating the feasibility of partial breast irradiation using a single fraction of IORT delivered to the tumor in vivo prior to surgical resection...
  13. ncbi request reprint Influence of provider and practice characteristics on melanoma care
    Karyn B Stitzenberg
    Department of Surgery, University of North Carolina, 3010 Old Clinic Building, CB 7213, Chapel Hill, NC 27599 7213, USA
    Am J Surg 193:206-12. 2007
    ..The purpose of this study is to describe the structure of melanoma care in North Carolina by examining services provided by different providers and the overall coordination of care...
  14. ncbi request reprint The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes
    Lisa A Carey
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    Clin Cancer Res 13:2329-34. 2007
    ..Gene expression analysis identifies several breast cancer subtypes. We examined the relationship of neoadjuvant chemotherapy response to outcome among these breast cancer subtypes...
  15. ncbi request reprint Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma
    Nancy E Thomas
    Department of Dermatology, University of North Carolina, Chapel Hill, NC 27599, USA
    Cancer Epidemiol Biomarkers Prev 16:991-7. 2007
    ..The association of BRAF mutations with early-life UV exposure provides evidence in support of childhood sun protection for melanoma prevention...
  16. doi request reprint Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging
    Michael O Meyers
    Department of Surgery and The Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7213, USA
    Ann Surg Oncol 16:941-7. 2009
    ..The purpose of this study was to determine the impact of routine imaging on the method of detection of first recurrence in patients with stage II and sentinel lymph node-positive stage III melanoma...
  17. ncbi request reprint Postoperative hypocalcemia after parathyroidectomy for renal hyperparathyroidism in the era of cinacalcet
    Michael O Meyers
    Department of Surgery, University of North Carolina School of Medicine at Chapel Hill, CB 7213, 105 Manning Drive, P O Box 1031, Chapel Hill, NC 27599 7213, USA
    Am Surg 75:843-7. 2009
    ..This may be useful to inform physicians and patients of expectations postoperatively, although it is not likely to alter management...
  18. doi request reprint Age and Breslow depth are associated with a positive sentinel lymph node in patients with cutaneous melanocytic tumors of uncertain malignant potential
    Michael O Meyers
    Department of Surgery, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC 27599 7213, USA
    J Am Coll Surg 211:744-8. 2010
    ..However, it is unclear whether this is required in all patients. We present our experience with sentinel lymphadenectomy in these patients and examine the clinical and pathologic variables associated with a positive SLN...
  19. pmc Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival
    William G Cance
    Department of Surgery, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 27599, USA
    Ann Surg 236:295-302; discussion 302-3. 2002
    ..The authors determined the rate of breast preservation, the disease-free and overall survival, and the factors associated with locoregional and distant recurrent disease...
  20. ncbi request reprint Tandem BRAF mutations in primary invasive melanomas
    Nancy E Thomas
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    J Invest Dermatol 122:1245-50. 2004
    ..The finding of tandem mutations in thin melanomas makes it more likely that they arise as a simultaneous rather than sequential event...
  21. ncbi request reprint Staged sentinel lymph node biopsy before mastectomy facilitates surgical planning for breast cancer patients
    Nancy Klauber-Demore
    Division of Surgical Oncology, University of North Carolina at Chapel Hill, 3010 Old Clinic Bldg, CB No 7213, Chapel Hill, NC 27599, USA
    Am J Surg 190:595-7. 2005
    ..The purpose of this study was to determine how performing an SLN biopsy (SLNB) before the definitive operation would influence subsequent surgical procedures...
  22. ncbi request reprint High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer
    Nancy Klauber-Demore
    Department of Surgery, University of North Carolina at Chapel Hill, 3010 Old Clinic Bldg, CB No 7213, Chapel Hill, NC 27599, USA
    Am J Surg 188:386-9. 2004
    ..The purpose of this study was to evaluate the efficacy of high-resolution axillary ultrasound in detecting axillary lymph node metastases after neoadjuvant chemotherapy in patients with locally advanced breast cancer...
  23. ncbi request reprint Cutaneous melanoma: update on prevention, screening, diagnosis, and treatment
    Erika L Rager
    Department of Surgery, University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina, USA
    Am Fam Physician 72:269-76. 2005
    ..Preventive strategies for melanoma should emphasize seeking shade when outdoors, wearing protective clothing, and avoiding exposure during the peak sunlight hours...
  24. ncbi request reprint Size of residual lymph node metastasis after neoadjuvant chemotherapy in locally advanced breast cancer patients is prognostic
    Nancy Klauber-Demore
    Department of Surgery, University of North Carolina at Chapel Hill, 27599, USA
    Ann Surg Oncol 13:685-91. 2006
    ..We examined the residual lymph node metastasis size in patients after treatment with neoadjuvant chemotherapy to determine the relevance of metastasis size on outcome...
  25. ncbi request reprint Population-based analysis of lymphatic mapping and sentinel lymphadenectomy utilization for intermediate thickness melanoma
    Karyn B Stitzenberg
    Department of Surgery, University of North Carolina, Chapel Hill, North Carolina 2755 7590, USA
    J Surg Oncol 93:100-7; discussion 107-8. 2006
    ..We hypothesize that a significant portion of these patients are not undergoing LM/SL. We explore factors that influence use of LM/SL...
  26. ncbi request reprint American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome
    Lisa A Carey
    Division of Hematology Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    J Natl Cancer Inst 97:1137-42. 2005
    ....
  27. ncbi request reprint Cytokeratin immunohistochemical validation of the sentinel node hypothesis in patients with breast cancer
    Karyn B Stitzenberg
    Department of Surgery, University of North Carolina, Chapel Hill 27599, USA
    Am J Clin Pathol 117:729-37. 2002
    ..node most likely to harbor metastatic tumor Standardization of the handling, sectioning, and staining of the SN is necessary as lymphatic mapping and sentinel lymphadenectomy become integrated into the care of patients with breast cancer..
  28. ncbi request reprint Experienced radio-guided surgery teams can successfully perform minimally invasive radio-guided parathyroidectomy without intraoperative parathyroid hormone assays
    Abigail S Caudle
    Department of Surgery, University of North Carolina, Chapel Hill, USA
    Am Surg 72:785-9; discussion 790. 2006
    ..This correlates with reported success rates of 95 per cent to 100 per cent using iPTH. We conclude that minimally invasive parathyroidectomy can be successfully performed without using iPTH assays...
  29. ncbi request reprint Successful minimally invasive parathyroidectomy for primary hyperparathyroidism without using intraoperative parathyroid hormone assays
    David W Ollila
    Division of Surgical Oncology, University of North Carolina, 3010 Old Clinic Building, CB 7213, Chapel Hill, NC 27599, USA
    Am J Surg 191:52-6. 2006
    ..The need for intraoperative parathyroid hormone (iPTH) assays in minimally invasive parathyroidectomy (MIP) remains controversial. We report the results of MIP performed without the use of iPTH assays...
  30. ncbi request reprint Prophylaxis and screening options: recommendations for young women with BRCA mutations
    Jonathan C Samuel
    Division of Surgical Oncology, University of North Carolina at Chapel Hill, 3010 Old Clinic Building, CB 7213, 27599 7213, USA
    Breast Dis 23:31-5. 2005
    ....
  31. ncbi request reprint Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine
    Eddy C Hsueh
    Sonya Valley Ghidossi Vaccine Laboratory, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    J Clin Oncol 20:4549-54. 2002
    ..Because melanoma is immunogenic, we investigated whether a therapeutic cancer vaccine called Canvaxin (CancerVax Corporation, Carlsbad, CA) could enhance antitumor immune responses and thereby prolong survival...
  32. ncbi request reprint Sentinel lymph node biopsy during pregnancy: initial clinical experience
    Matthew M Mondi
    Surgical Oncology Services, Wake Forest University, Winston Salem, North Carolina, USA
    Ann Surg Oncol 14:218-21. 2007
    ....
  33. ncbi request reprint Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma
    Reiko F Irie
    Department of Biotechnology Sciences, John Wayne Cancer Institute, Saint John s Health Center, 2200 Santa Monica Blvd, CA 90404, Santa Monica, USA
    Cancer Immunol Immunother 53:110-7. 2004
    ..All patients received a 48-h continuous infusion of L612 HuMAb at a dose of 960 mg, 1,440 mg, or 1,920 mg. Five of these patients received a second infusion and one patient received a third infusion, all with the previous dose...